Effect of AY-25,712 and other lipid-lowering agents on liver catalase and liver carnitine acetyltransferase in rats. 1983

M A Kallai-Sanfacon, and M N Cayen, and J Dubuc, and E Greselin, and D Dvornik

The effect of the hypolipidemic agent AY-25,712 on liver catalase and carnitine acetyltransferase was studied in rats. At 250 mg/kg/day for 2 or 4 weeks, i.e., at least 125 times the minimum effective hypolipidemic dose, AY-25,712 had no effect on liver weight or liver catalase. Liver catalase was elevated after a 2-week treatment with clofibrate (+ 30%), bezafibrate (+71%), and fenofibrate (+77%) at doses of 250 mg/kg/day, and with ciprofibrate (+111%) at 25 mg/kg/day. Gemfibrozil at 250 mg/kg/day for 4 weeks increased catalase by 86%. The relative increase in liver weight induced by these compounds showed a good correlation to increased catalase. Nicotinic acid (250 mg/kg/day for 2 weeks) did not alter liver weight or catalase. Clofibrate increased carnitine acetyltransferase by 176% while AY-25,712 had no effect. The results show that AY-25,712 and nicotinic acid did not induce changes in the livers of rats which are associated with treatment by various other hypolipidemic agents.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D009929 Organ Size The measurement of an organ in volume, mass, or heaviness. Organ Volume,Organ Weight,Size, Organ,Weight, Organ
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D002332 Carnitine O-Acetyltransferase An enzyme that catalyzes the formation of O-acetylcarnitine from acetyl-CoA plus carnitine. EC 2.3.1.7. Carnitine Acetyltransferase,Carnitine-Acetyl-CoA-Transferase,Acetyltransferase, Carnitine,Carnitine Acetyl CoA Transferase,Carnitine O Acetyltransferase,O-Acetyltransferase, Carnitine
D002374 Catalase An oxidoreductase that catalyzes the conversion of HYDROGEN PEROXIDE to water and oxygen. It is present in many animal cells. A deficiency of this enzyme results in ACATALASIA. Catalase A,Catalase T,Manganese Catalase,Mn Catalase
D005663 Furans Compounds with a 5-membered ring of four carbons and an oxygen. They are aromatic heterocycles. The reduced form is tetrahydrofuran. Tetrahydrofurans
D000123 Acetyltransferases Enzymes catalyzing the transfer of an acetyl group, usually from acetyl coenzyme A, to another compound. EC 2.3.1. Acetyltransferase
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000960 Hypolipidemic Agents Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. Antihyperlipidemic,Antilipemic,Antilipemic Agents,Antilipemic Drug,Hypolipidemic Agent,Hypolipidemic Drug,Antihyperlipemics,Antihyperlipidemics,Antilipemic Drugs,Antilipemics,Hypolipidemic Drugs,Agent, Hypolipidemic,Agents, Antilipemic,Agents, Hypolipidemic,Drug, Antilipemic,Drug, Hypolipidemic,Drugs, Antilipemic,Drugs, Hypolipidemic

Related Publications

M A Kallai-Sanfacon, and M N Cayen, and J Dubuc, and E Greselin, and D Dvornik
August 1983, Clinical biochemistry,
M A Kallai-Sanfacon, and M N Cayen, and J Dubuc, and E Greselin, and D Dvornik
February 1980, Journal of pharmaceutical sciences,
M A Kallai-Sanfacon, and M N Cayen, and J Dubuc, and E Greselin, and D Dvornik
February 2017, Liver international : official journal of the International Association for the Study of the Liver,
M A Kallai-Sanfacon, and M N Cayen, and J Dubuc, and E Greselin, and D Dvornik
March 1979, Journal of biochemistry,
M A Kallai-Sanfacon, and M N Cayen, and J Dubuc, and E Greselin, and D Dvornik
October 1979, MMW, Munchener medizinische Wochenschrift,
M A Kallai-Sanfacon, and M N Cayen, and J Dubuc, and E Greselin, and D Dvornik
August 2003, Deutsche medizinische Wochenschrift (1946),
M A Kallai-Sanfacon, and M N Cayen, and J Dubuc, and E Greselin, and D Dvornik
December 1994, British journal of clinical practice. Supplement,
M A Kallai-Sanfacon, and M N Cayen, and J Dubuc, and E Greselin, and D Dvornik
January 1996, British journal of clinical practice. Supplement,
M A Kallai-Sanfacon, and M N Cayen, and J Dubuc, and E Greselin, and D Dvornik
June 1985, Atherosclerosis,
M A Kallai-Sanfacon, and M N Cayen, and J Dubuc, and E Greselin, and D Dvornik
October 1978, Lancet (London, England),
Copied contents to your clipboard!